Hydromorphone

Hydromorphone is regulated as a controlled substance under the Controlled Substances Act.⁷³ Selling it requires a DEA license, and buying or possessing it is unlawful unless covered by a valid license or prescription. It is classified as having a high potential for addiction while also having accepted medical use.

Controlled under Schedule I of the Controlled Drugs and Substances Act.¹¹ Note that Canadian schedules differ significantly from US scheduling classifications.

Hydromorphone, listed as hydromorfon, appears in List I of the current Dutch Opium Act. Article 2 prohibits importing or exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing List I substances, subject to the Act's statutory exceptions and exemptions.

Singapore’s First Schedule lists Hydromorphone as a Class A controlled drug (item 67). Except as authorised under the Misuse of Drugs Act, possession and consumption of a controlled drug are offences; trafficking and import or export are separately prohibited.

Controlled under the Misuse of Drugs Act 1971.⁷⁰ Class A designation carries the most severe penalties for unauthorized possession or supply. Schedule 2 permits medical prescribing under strict controls.⁷¹

Under Colombia's current technical annex, hydromorphone is classified as a substance under State monopoly. The same resolution separately lists hydromorphone hydrochloride as a State-monopoly special-control medicine. Resolution No. 116 took effect on 27 January 2026 and replaces the technical annexes adopted by Resolution No. 315 of 2020.

Under Federal Law No. 3-FZ, List II covers narcotic drugs and psychotropic substances whose turnover is restricted and subject to control; the same law defines illegal consumption as use without a doctor's prescription and defines dispensing to individuals as transfer for medical purposes. Current Order No. 100n expressly includes rules for dispensing narcotic and psychotropic substances registered as medicinal products, while Order No. 1094n governs prescribing and prescription forms. A medical prescription pathway therefore exists for registered medicinal products; current registration or stocking of a hydromorphone product in Russia is not established. Unauthorized possession/acquisition/transport/manufacture without intent to sell is addressed by Criminal Code Article 228 (up to 3 years for significant size, 3–10 years for large size, 10–15 years for especially large size); illicit production, sale or dispatch is addressed by Article 228.1 (4–8 years for the base offense, with qualified cases reaching 5–12, 8–15, 10–20, or 15–20 years or life imprisonment). The exact charge depends on conduct, amount and aggravating circumstances. The official Government Criminal Code page lists amendments through Federal Law No. 164-FZ of 10.06.2026; the official thresholds resolution lists amendments through Resolution No. 880 of 11.06.2025.

South Korea's current Enforcement Decree lists hydromorphone (하이드로모르폰) in Annex 1 as a narcotic under Article 2(2)(d) of the Narcotics Control Act. The Annex provides that this class includes the named substances and their salts.

TİTCK's official 07.08.2024 red-prescription list expressly lists Jurnista 4, 8, 16, 32 and 64 mg products, each with ATC name hydromorphone and a maximum of 1 box (28 days). TİTCK's controlled-substances page explains that its unit regulates the medical trade in narcotic and psychotropic substances under Turkish legislation and the 1961/1971 conventions. The current TİTCK licensed-human-products list (21.08.2026) contains no Jurnista or hydromorphone row. For criminal exposure, TCK Article 188(3) sets at least 10 years' imprisonment plus 1,000–20,000 judicial days for unauthorised domestic sale, offering, giving, transport, storage, purchase, acceptance or possession of narcotic/psychotropic substances; Article 188(6) applies the provisions to substances whose production requires official permission or whose sale requires an authorised physician prescription. Article 191(1) sets 2–5 years for purchase, acceptance, possession or use for personal use, with the treatment-oriented deferred-prosecution and supervised-treatment framework in Article 191(2)–(4). The Adalet Bakanlığı consolidation's amendment table shows Articles 188 and 191 last amended by Law 7445 effective 05.04.2023, and the table runs through Law 7550 effective 04.06.2025; accessed 2026-08-28.

Controlled drug under the Poisons Standard. Illegal to possess without a valid prescription or license. Schedule 8 substances are those with high abuse potential requiring restricted supply.

Legal for medical use under the Arzneimittelgesetz (AMG). Possession or sale without a valid prescription is illegal under the Suchtmittelgesetz (SMG - Narcotics Act).⁷⁸

Hidromorfona is in Brazil's List A1 of narcotic substances. It is subject to the special prescription and dispensing controls that apply to listed narcotic medicines.

Chile’s current Reglamento de Estupefacientes lists hidromorfona (dihidromorfinona) in List I. Article 23 provides that products containing substances in Lists I and II may be dispensed to the public by pharmacies or laboratories only with a receta cheque or receta médica retenida, according to the product’s sale condition.

The current e-Sbírka consolidation of Government Regulation No. 463/2013 Coll. expressly lists Hydromorfon in List No. 1 of narcotic substances; the current consolidated text does not list it in List No. 8. Under Section 13(1) of Act No. 167/1998 Coll., a medicinal product containing a List No. 1 substance not also in List No. 8 may be prescribed by a physician and supplied by a pharmacist only on the specified high-addictiveness electronic prescription, blue-stripe paper prescription, or blue-stripe requisition.

Hydromorphon (INN) is listed at no. 229 of List B in Denmark's current executive order on euphoriant substances. List B substances may be used only for medical or scientific purposes; the order permits patients to receive and possess them under a prescription or treatment arrangement.

Controlled substance under Anlage III of the Betäubungsmittelgesetz (Narcotics Act).¹⁸ Can only be prescribed using a narcotic prescription form (Betäubungsmittelrezept).

Hydromorphone is expressly listed in Schedule 2 of the Misuse of Drugs Regulations 2017. The Regulations prohibit production, supply, importation, and export except as authorised, and allow possession for medical, dental, or veterinary administration under a practitioner's directions; Schedule 2 prescriptions and dispensing are subject to the Regulations' prescription requirements.

Under the current D.P.R. 309/1990, section A of the medicines table covers medicinal products containing natural, semi-synthetic, or synthetic opioid analgesics. Hydromorphone supplied as such a medicinal product is therefore in section A. Section A medicines require the Ministry-approved prescription form and are ordinarily limited to a thirty-day course; the statute preserves any further AIFA authorization conditions.

ヒドロモルフォン is a narcotic under Japan's narcotics-control framework. Its import, export, manufacture, transfer and medical handling are regulated under the Act and the controlled-medicines system.

Mexico's current General Health Law lists hydromorphone (dihydromorphinone) as an estupefaciente. Medicines in the law's narcotics chapter may be acquired only with a special prescription or permit, and prescriptions for estupefacientes must use special prescription forms with a barcode assigned by the health authority. Hydromorphone is therefore available only through Mexico's special-prescription narcotics-control regime.

Hydromorphone is classified as a prescription medicine in New Zealand. It is also a Class B3 controlled drug under the Misuse of Drugs Act 1975. The Ministry of Health's current Medicines Classification Database records both classifications for hydromorphone, drawing them from Schedule 1 of the Medicines Regulations 1984 and the schedules to the Misuse of Drugs Act 1975.

Hydromorphone is listed in the Philippine Schedules of Dangerous Drugs. It is regulated within the Comprehensive Dangerous Drugs Act framework for controlled substances.

Hydromorphone (HYDROMORFON) is expressly listed at item 84 of the Group I-N narcotic-drugs schedule. Article 33(1) allows Group I-N drugs only for medical, industrial, or research purposes. Under Article 41(2), preparations containing narcotic drugs are dispensed by pharmacies only on a specially marked prescription or requisition; this dispensing rule for preparations does not constitute a general authorization to possess the substance. The 2025 and 2026 amendments to the schedule do not amend item 84.

LVFS 2011:10 states that Swedish lists II–IV cover substances with medical use, and its table maps Hydromorfon to Dihydromorfinon with Swedish list II and international list N I. Palladon 2.6 mg hard capsule is a prescription medicine (receptbelagt) with ATC N02AA03. The current Swedish Narcotic Drugs Penal Act makes unlawful possession, use and other handling criminal; ordinary narcotics offences carry up to three years, petty offences fines or up to six months, gross offences two to seven years, and exceptionally gross offences six to ten years, with separate sale-related minimums. The regulator schedule is consolidated through HSLF-FS 2026:26, the narcotics-control ordinance is amended through SFS 2026:1109, and the Penal Act is amended through SFS 2024:797.

Controlled substance specifically listed under Verzeichnis A of Swiss narcotics legislation. Medicinal use is permitted with appropriate authorization.

Hydromorphone (dihydromorphinone) is listed in Table II, List No. 1 of Ukraine's national controlled-substances list, which covers narcotic drugs and plants whose circulation is restricted. Under Article 27 of Law No. 60/95-VR, an individual may acquire a medicinal product containing a Table II substance for medical indications only on an electronic doctor's prescription; retail supply is likewise by electronic prescription from a licensed pharmacy.